Roche, the parent company of Chugai Pharmaceutical, announced that it had obtained U.S. FDA approval for Enspryng, a treatment for autoimmune diseases, for thyroid eye disease. Enspryng is presented as a treatment that can be administered by subcutaneous injection and also at home.
Roche, the parent company of Chugai Pharmaceutical, announced that Enspryng had obtained approval from the U.S. Food and Drug Administration (FDA) for thyroid eye disease.
Enspryng can be administered by subcutaneous injection and is also reportedly suitable for at-home administration. It has been reported that this makes it one treatment option for thyroid eye disease.
The article includes links to related information, as well as supplementary information on the company's profile and future developments.